<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01049854</url>
  </required_header>
  <id_info>
    <org_study_id>L 10,321</org_study_id>
    <secondary_id>NYMC 525</secondary_id>
    <nct_id>NCT01049854</nct_id>
  </id_info>
  <brief_title>CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant</brief_title>
  <official_title>CD34+Stem Cell Selection for Patients Receiving Partially Matched Family or Matched Unrelated Adult Donor Allogeneic Stem Cell Transplantations for Malignant and Non-Malignant Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York Medical College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York Medical College</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      CD34+ stem cell selection in children, adolescents and young adults receiving partially
      matched family donor or matched unrelated adult donor allogeneic bone marrow or peripheral
      blood stem cell transplant will be safe and well tolerated and be associated with a low
      incidence of serious (Grade III/IV) acute and chronic graft versus host disease (GVHD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The selection of CD34+ cells is associated with the simultaneous depletion of T cells that
      are responsible for severe acute and chronic graft versus host disease (GVHD). Successful
      engraftment is reported in adult patients with malignant and non-malignant disease who
      received CD34+ selected stem cells from HLA-matched or mismatched mobilized peripheral blood
      (PBSC) or bone marrow.

      Study Design:

      Selected patients defined in the eligibility criteria will enrolled on this study. Patients
      will receive one of either full intensity or reduced intensity regimen based on the patient's
      disease status, organ function and performance and determined by the PI and will have
      peripheral blood undergo CD34 selection.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The safety CD34+ stem cell selection</measure>
    <time_frame>100 days</time_frame>
    <description>serious adverse events will be monitored post transplant to determine if there is an increase vs. historical data related to the CD34+ selection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune reconstitution (T, B, DC) following CD34+ selection</measure>
    <time_frame>3 years</time_frame>
    <description>immune subsets will be drawn post transplant to determine the rate of reconstitution post CD34+ transplant to determine if this process increases or decreases the reconstitution time.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Bone Marrow Failure</condition>
  <condition>Immunodeficiencies</condition>
  <condition>Histiocytosis</condition>
  <condition>Sickle Cell Disease</condition>
  <condition>Beta Thalassemia</condition>
  <condition>Inborn Errors of Metabolism</condition>
  <arm_group>
    <arm_group_label>Thiotepa/Cyclophosphamide/ATG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Full intensity with TBI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Busulfan/Melphalan/ATG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Full intensity without TBI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Busulfan/Fludarabine/Alemtuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Reduced Intensity Chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fludarabine/Cyclophosphamide/ATG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Reduced Intensity Chemotherapy for Fanconi Anemia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Full Intensity with TBI</intervention_name>
    <description>Patients will start their pre-conditioning regimen on Day -8. Fractionated TBI will be administered twice daily for 3 days on Days -8, -7, and -6. Patients will receive Thiotepa on Days -5, -4, Cyclophosphamide on Days -3, -2 and rabbit antithymocyte globulin on Days -4, -3, -2 and -1. The stem cell infusion will be performed on Day 0. GM-CSF hematopoietic growth factor will start on Day 0. GVHD prophylaxis will consist of tacrolimus only.</description>
    <arm_group_label>Thiotepa/Cyclophosphamide/ATG</arm_group_label>
    <other_name>ThioTepa</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Atgam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Full Intensity</intervention_name>
    <description>Patients will start their pre-conditioning regimen on Day -9. Patients will receive busulfan twice daily on Days - 8, -7, -6, and -5 and Melphalan on Days -4, -3 and -2 and rabbit antithymocyte globulin on Days -4, -3, -2 and -1 with stem cell infusion on Day 0. GM-CSF hematopoietic growth factor will start on Day 0. GVHD prophylaxis will consist of tacrolimus only.</description>
    <arm_group_label>Busulfan/Melphalan/ATG</arm_group_label>
    <other_name>Myleran</other_name>
    <other_name>Alkeran</other_name>
    <other_name>Atgam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reduced Intensity</intervention_name>
    <description>Patients will start their GVHD prophylaxis with Tacrolimus on Day -9. Patients will receive busulfan twice daily on Days -8, -7, -6, and -5; fludarabine on Days -7, -6, -5, -4, -3 and -2 and alemtuzumab on Days -5, -4, -3, -2, and -1. The stem cell infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus only.</description>
    <arm_group_label>Busulfan/Fludarabine/Alemtuzumab</arm_group_label>
    <other_name>Fludara</other_name>
    <other_name>Myleran</other_name>
    <other_name>Campath</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reduced Intensity (Fanconi)</intervention_name>
    <description>Patients will start their pre-conditioning regimen on Day -6. Patients will receive TBI as a single fraction on Day -6. Patients will receive fludarabine and cyclophosphamide on Days - 5, -4, -3, and -2 and antithymocyte globulin (horse) on Days -5, -4, -3, -2 and -1. The stem cell infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus only.</description>
    <arm_group_label>Fludarabine/Cyclophosphamide/ATG</arm_group_label>
    <other_name>Fludara</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Atgam</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adequate renal function defined as:Serum creatinine &lt;1.5 x normal, or Creatinine
             clearance or radioisotope GFR &gt;60 ml/min/m2 or an equivalent GFR as determined by the
             institutional normal range.

          -  Adequate liver function defined as:Total bilirubin &lt;1.5 x normal, or SGOT (AST) or
             SGPT (ALT) &lt;3.0 x normal

          -  Adequate cardiac function defined as:Shortening fraction &gt;27% by echocardiogram, or
             Ejection fraction of &gt;47% by radionucleotide angiogram or echocardiogram.

          -  Adequate pulmonary function defined as:Uncorrected DLCO &gt;50% by pulmonary function
             test. For children who are uncooperative, no evidence of dyspnea at rest, no exercise
             intolerance, and a pulse oximetry &gt;94% on room air.

        Eligibility for Reduced Intensity Regimen:

          -  Adequate renal function defined as:Serum creatinine 2.0 x normal, or creatinine
             clearance or radioisotope GFR &gt; 40 ml/min/m2 or an equivalent GFR as determined by the
             institutional normal range.

          -  Adequate liver function defined as:Total bilirubin &lt; 2.5 x normal; or SGOT (AST) or
             SGPT (ALT) &lt; 5.0 x normal.

          -  Adequate cardiac function defined as:Shortening fraction of &gt;25% by echocardiogram, or
             Ejection fraction of &gt;40% by radionuclide angiogram or echocardiogram.

          -  Adequate pulmonary function defined as:DLCO &gt;35% by pulmonary function test. For
             children who are uncooperative, no evidence of dyspnea at rest, no exercise
             intolerance, and a pulse oximetry &gt;94% in room air.

        Exclusion Criteria:

          -  Pregnancy/Breast Feeding: Females who are pregnant or breast-feeding are not eligible.

          -  Infection: Patients with documented uncontrolled infection at the time of study entry
             are not eligible.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitchell S Cairo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York Medical College</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2008</study_first_submitted>
  <study_first_submitted_qc>January 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2010</study_first_posted>
  <last_update_submitted>April 6, 2018</last_update_submitted>
  <last_update_submitted_qc>April 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York Medical College</investigator_affiliation>
    <investigator_full_name>Mitchell Cairo</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>unrelated donor transplant</keyword>
  <keyword>CD34 selection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
    <mesh_term>Histiocytosis</mesh_term>
    <mesh_term>Pancytopenia</mesh_term>
    <mesh_term>Metabolism, Inborn Errors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

